Further analysis stratified by CVD subtypes (stroke, PAOD, heart failure, arrhythmia, cerebrovascular accident, and coronary artery disease) revealed that IFN‐based therapy and attainment of SVR were not significantly associated with CVD event rates across any subtype (Figure 2b–g, Table 2). This evidence concerns the gene IFNA1 and Stroke.